Investor Presentaiton
•
Q3 and 9 Months FY24 performance
Operating Highlights
The third quarter was underpinned by positive performance in Development and
Manufacturing Services as well as in the Dedicated Centers. Performance in
Discovery Services was impacted by the slowdown in biotech funding
In Manufacturing Services, the Company continued to make good progress on the
long-term biologics manufacturing partnership with Zoetis.
Syngene concluded the acquisition of biologics manufacturing facility from Stelis
Biopharma Ltd. Once operational, the acquisition will add 20,000 litres of biologics
drug substance manufacturing capacity to Syngene's existing capabilities. It also
includes a commercial scale, high speed, fill-finish unit, which is an essential
capability for drug product manufacturing. The facility is expected to be
operational in the second half of FY25, subject to regulatory approvals.
In Discovery Services, the Company added an assay biology capability at the
Hyderabad campus to complement the existing Drug Metabolism and
Pharmacokinetics (DMPK) and Compound Management facilities
Updated guidance: Revenue growth for the full year around double digits on a constant
currency basis compared to earlier guidance of mid teens growth
Syngene
Q3 Financial Highlights
Revenue from Operations: 9% YoY
Total Revenue: Rs 8,828 Mn
Reported EBITDA: Rs 2,608 Mn
Profit After Tax*: Rs 1,145 Mn
EBITDA from operations margin 27%
Profit after Tax* margin 13%
PAT✶ 4% YOY
9 Months FY24 Financial Highlights
Revenue from Operations: 17% YoY
*before exceptional items
Total Revenue: Rs 26,462 Mn
Reported EBITDA: Rs 7,720 Mn
Profit After Tax*: Rs 3,299 Mn
EBITDA from operations margin 27%
PAT* 16% YoY
Putting Science to Work
5View entire presentation